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p300 is a transcriptional cofactor and prototype histone acetyltransferase involved in regulating multiple cellular processes. We
generated p300 deficient (p300) cells from the colon carcinoma cell line HCT116 by gene targeting. Comparison of epithelial and
mesenchymal proteins in p300 with parental HCT116 cells showed that a number of genes involved in cell and extracellular matrix
interactions, typical of ‘epithelial to mesenchyme transition’ were differentially regulated at both the RNA and protein level. p300
cells were found to have aggressive ‘cancer’ phenotypes, with loss of cell–cell adhesion, defects in cell–matrix adhesion and increased
migration through collagen and matrigel. Although migration was shown to be metalloproteinase mediated, these cells actually
showed a downregulation or no change in the level of key metalloproteinases, indicating that changes in cellular adhesion properties
can be critical for cellular mobility.
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p300 was initially cloned as an adenoviral E1A-binding protein and
subsequently characterised as a transcriptional coactivator with
histone acetyl transferase activity. It promotes gene transcription
by bridging DNA-binding transcription factors and the basal
transcription machinery, by providing a scaffold to integrate
transcription factors and by modifying the activity of transcription
factors and chromatin through direct acetylation of specific lysine
residues. p300 and its close homologue CREB-binding protein
(CBP) play a key role in a diverse array of cellular processes
including cell cycle regulation, proliferation, differentiation,
apoptosis, DNA damage repair and adhesion, as well as embryonic
development (Chan and La Thangue, 2001; Iyer et al, 2004b).
Mutations in p300/CBP have been found in a number of human
cancers. Bi-allelic somatic mutations in the p300 gene have been
identified in gastric, colon and breast cancers (primary tumours
and cancer cell lines), and some of these mutations clearly result in
inactivated or truncated protein products (Muraoka et al, 1996;
Gayther et al, 2000; Ozdag et al, 2002). While this gave rise to the
view that p300 could function as a classical tumour suppressor, it
is still unclear how a loss of p300 and CBP could contribute to
tumorigenesis (Goodman and Smolik, 2000).
It has been recently proposed that a major process contributing
to tumour progression is epithelial to mesenchyme transition
(EMT) (Thiery, 2002). Epithelial to mesenchyme transition
describes the de-differentiation of polarised epithelial cells to
mesenchymal cells, which characteristically have a more motile
phenotype. Such a loss of epithelial characteristics is often found in
carcinomas with a greater malignant potential and EMT is believed
to occur during the transition of adenomas to adenocarcinomas
in colorectal cancer (Thiery, 2002). Extracellular matrix (ECM)
degrading proteases (including serine-, metallo- and cysteine
proteases) play a key role in the invasion of tumour cells, and these
could function as the mediators of the EMT-induced invasiveness.
In this study, we used a somatic cell line knockout model to
study the cancer phenotype induced by disrupting p300 (Iyer et al,
2004a). Loss of p300 in HCT116 cells results in a potentially
aggressive phenotype characterised by reduced adhesion and
increased migration. In addition, several critical genes involved in
these pathways are differentially expressed, suggesting that p300
loss promotes EMT.
MATERIALS AND METHODS
Cell culture, generation of p300 and rescue cells
HCT116 (ATCC, Manassas, VA, USA) and its derivatives were
cultured in McCoy’s 5A medium with 10% fetal calf serum (FCS)
and penicillin/streptomycin (Invitrogen, Paisley, UK). p300 gene
targeting was performed as previously described (Iyer et al, 2004a).
HCT116 cells were chosen because they are amenable to
homologous gene recombination and p300 has been found to be
mutated in many colorectal cancers. Briefly, the single expressed
p300 allelle in HCT116 was targeted by homologous recombination
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resulting in cells null for any expressed p300 protein. Three
separately targeted clones were derived and used in each
experiment. Rescue clones were made by co-transfecting pcDEF-
Flag-p300 (kind gift from MA Ikeda) (Suganuma et al, 2002),
with pPGK-Puro at a 10 : 1 ratio, and selecting with 1 mg ml1
Puromycin (Sigma, Cambridge, UK) for 24 h. Two separate EF-wt
rescue clones were derived and used in each experiment. p300
expression levels in each clone were determined at the start of
every experiment. Rescue cells were generated using a p300
expression construct under the control of an EF-promoter (human
elongation factor 1a promoter). This was preferred as it resulted in
stable expression over longer time periods (Suganuma et al, 2002).
Immunofluorescence localisation
Cells were cultured on cover slips, fixed with 4% paraformaldehyde
(PFA) solution, blocked with 1 mM glycine (pH 7.5) and
permeabilised for 4 min in 0.1% Triton. Immunofluorescent
detection was carried out in duplicate (Roghi and Allan, 1999).
The primary antibodies used were: E-cadherin (BC Biosciences,
San Jose, CA, USA, 1 : 50), ZO-1 (Invitrogen, Zymed, Paisley, UK,
1 : 100), b-catenin (Transduction Labs, 1 : 50), Vimentin (DAKO,
1 : 50). The AlexaFluor 488 conjugated anti-mouse antibody
(Invitrogen, Molecular Probes, Paisley, UK, 1 : 500) was the
secondary antibody in all cases. Pictures were taken with a  63
objective.
Western blots
Cells were harvested in protein lysis buffer (50 mM Tris/HCl,
150 mM NaCl, 1% NP-40 v v1, 10 mM EDTA, Completet Inhibitor
Cocktail 1 tablet 10 ml1 (Roche Diagnostics, Welwyn Garden City,
UK)). Samples were subjected to reducing SDS–PAGE and
transferred to nitrocellulose using a semidry blotter. The
membranes were blocked in 5% fat-free milk and subsequently
incubated in the primary and secondary antibody solution for 1 h
each. Blots were visualised using the Enhanced chemi-lumines-
cence detection system from Amersham. All experiments and blots
were performed in triplicate and representative examples are
shown in the figures. Cytosolic and nuclear fractions were obtained
with the BioVision Nuclear/Cytosol Fractionation Kit. Membrane
fractionation was performed as previously described (Smith et al,
2005). Primary antibodies were mouse monoclonal E-cadherin
(Zymed; 1 : 500), Vimentin (DAKO; 1 : 250), ZO-1(Zymed; 1 : 500),
a-tubulin (B-152; 1 : 5000), the polyclonal rabbit anti-p300 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA, 1 : 200) and anti-b-actin
(ab8227; 1 : 5000). The secondary antibody was a sheep anti-mouse
or a donkey anti-rabbit horseradish peroxidase conjugated
monoclonal antibody (Jackson Immuno Research Europe, Soham,
UK, 1 : 5000).
Matrigel growth
For three-dimensional (3-D) cultures, cells were plated at a density
of 1 105 cm2 onto reconstituted (pre-gelled) basement mem-
brane (Matrigel; BD Biosciences, San Jose, CA, USA) in DMEM/F12
media with 2% FCS. Cells were incubated for 18 h and
photographed live by phase microscopy. For quantification of
cluster sizes, cells were subsequently fixed in 4% PFA in PBS for
10 min and nuclei stained with 0.5 mg ml1 DAPI for 5 min. Cells
were mounted, and cluster sizes were determined by counting
nuclei using a Zeiss Axiphot microscope equipped for epifluores-
cence. For immunoflurescence, 3-D basement membrane cultures
of cells were maintained on glass coverslips and grown to
subconfluence. Cells were fixed with methanol for 15 min, rinsed
three times with PBS and blocked in PBS with 1% bovine serum
albumin (BSA).
Determination of integrin cell surface levels
Cell surface levels of integrins were quantified by flow cytometry.
Cells, 2.5 105,were detached using 5 mM EDTA in PBS, centri-
fuged at 200 g for 4 min and washed in ice-cold PBS three times.
All reagents used from this stage on were precooled on ice. Cells
were incubated in 100ml PBS containing 0.5% BSA and the primary
antibody at 10 mg ml1 for 1 h on ice (integrin a2 was purchased
from Dianova, integrin a1 from Serotec, integrin a5 from DAKO,
integrin a6 from BD Pharmingen, integrin aV from Chemicon,
integrin b1 from BD Pharmingen, integrin b3 from Serotec). Cells
were washed in PBS/BSA and incubated in 100ml PBS/BSA solution
containing the secondary antibody (AlexaFluor 488 goat anti-
mouse, AlexaFluor 488 goat anti-rat 1 : 500 in the PBS/BSA
solution). The cells were fixed in 2% PFA for 20 min and washed
once in PBS. Experiments were conducted in duplicate.
Adhesion assay
Black immunotreated 96-well plates (Nunc maxisorb) were coated
overnight with the matrix components in coating buffer at
10 mg ml1 and blocked for 2 h with 100ml coating buffer/1%
BSA (Sigma Aldrich, Gillingham, UK) solution. As negative control
wells were blocked with the BSA solution only. Cells were removed
from their culture vessels with 5 mM EDTA in PBS and were dye
loaded with 2 mM CMFDA cell tracker dye (Molecular Probes)
according to the manufacturer’s protocol. 105 cells were incubated
in HBSS with 1 mM Mn2þ at 371C for 1.5 h in the coated wells. All
samples were analysed in quadruplicate. After incubation the
fluorescence was measured in a plate reader (Tecan Spectrafluor
Plus, excitation 485 nm, emission 595 nm). The wells were washed
5 with 200 ml HBSS. The fluorescent values of each sample were
averaged and the mean background value was subtracted. To
inhibit the adhesion mediated by integrin a2 an integrin a2 binding
antibody (Dianova, A.1.43) was added during the adhesion phase
of the assay. The antibody was used at concentrations between
1 mg ml1 and 30 mg ml1 for the inhibition of adhesion.
Boyden chamber migration assay
The relative migration of wild-type (WT) and p300 cells was
studied with an in vitro migration assay, conducted in Boyden
chambers (Becton Dickinson, 8 mm pores). The membrane of the
cell culture insert was coated with 100 ml collagen I (100mg ml1,
Sigma) or growth factor-reduced matrigel (200 ml ml1, BD
Biosciences, San Jose, CA, USA) in coating buffer (0.1 M NaHCO3
(pH 9.8)) for 16 h. WT and p300 HCT116 cells were dye loaded
with 2 mM CMFDA cell tracker dye (Molecular Probes). Cells,
2.5 105, were added to the cell culture insert and incubated for
22 h. Membranes were then fixed for 5 min in methanol at 201C,
mounted on a slide and 15 randomly chosen fields of view were
photographed at 40 magnification. Cells were counted, averaged
over the three membranes and expressed in relation to the WT.
cDNA Synthesis and qPCR
RNA was isolated with the Promega kit according to the
manufacturers protocol. In all, 1 mg of total RNA was reverse
transcribed using 2 mg random hexamers (Amersham Biosciences,
Amersham, UK) and 200 Units of Superscript II reverse tran-
scriptase (Invitrogen Life Technologies, Paisley, UK), according to
the supplier’s instructions. Quantitative polymerase chain reaction
(PCR) reactions were performed on a ABI Prism 7700 (Applied
Biosystems, Warrington, UK; (Nuttall et al, 2003), with each
reaction containing 5 ng of reverse-transcribed RNA. Primers and
fluorogenic probes for a selection of matrix metalloproteinase
(MMPs) and a disintegrin and metalloproteinase (ADAMs) were
p300 deficiency induces EMT
D Krubasik et al
1327
British Journal of Cancer (2006) 94(9), 1326 – 1332& 2006 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
obtained by courtesy of D Edwards, UEA, Norwich (Koshy et al,
2002; Nuttall et al, 2003).
RESULTS
Comparison of HCT116 and p300 cells reveals an
expression profile associated with EMT and a disruption in
cell-cell adhesion
HCT116 derivatives null for p300 (p300 cells) were generated as
previously described (Iyer et al, 2004a), and three independently
targeted p300 clones (p3001, p3002, p3003) were used for all
subsequent experiments. p300 expression was tested by Western
blot (Figure 1). To characterise the effect of p300 loss on gene
expression, cDNA microarray profiling was initially performed
using the 6 K genomewide cDNA microarrays (from ICR, Sutton,
UK) as previously described (Ahmed et al, 2004). Data from these
experiments showed that p300 cells have a gene expression
profile characteristic of EMT. These include a reduced expression
of several members of the cadherin and integrin families and
CD44. Downregulation of E-cadherin and upregulation of Vimen-
tin was observed in two of the three clones, but overall neither
were statistically significant (G Iyer and C Caldas, unpublished).
We therefore carried out an analysis of key adhesion molecules
using more reliable techniques. Immunostaining showed that E-
cadherin levels at adherens junctions were significantly lower in
p300 cells (Figure 2A). Reverse transcription –polymerase chain
reaction (RT –PCR) analyses (data not shown) and Western blot
(Figure 3A) confirmed reduced transcription of the E-cadherin
gene and reduced protein levels. b-Catenin and ZO-1 were found
to be redistributed in p300 cells (Figure 2A): decreased staining
of b-catenin and ZO-1 at cell–cell junctions and increased nuclear
b-catenin staining (Figure 2B). The increase in nuclear b-catenin
levels was verified by cellular fractionation and Western blot
(Figure 4A), while no change in cytosolic b-catenin was observed
(Figure 4B). Densitometry of three separate experiments showed
that the increase in nuclear b-catenin was statistically significant
(P-value o0.05, Figure 4B). Membrane fractionation confirmed
the reduced levels of ZO-1 localising to the membrane in the p300
cells in comparison to the WT cells (Figure 4C). Total cellular
levels of both proteins, determined by Western blots, remained
unchanged (data not shown). Immunostaining (Figure 2A) and
Western blots (Figure 3B) for the mesenchymal intermediate
filament Vimentin, showed that all three p300 clones expressed
significant amounts of the mesenchymal marker Vimentin (albeit
with varying degrees of heterogeneity), while levels were un-
detectable in HCT116 cells. These results suggest that loss of p300
is associated with changes characteristic of EMT in this colorectal
cancer cell line.
Loss of cell – cell junctions coincides with reduced
clustering in matrigel
To identify abnormalities in cell–cell adhesion, cells were grown in
reconstituted basement membrane (matrigel) based 3-D cultures.
Under these conditions, p300 cells grew in small, loosely adherent
clusters with ragged edges characteristic of cells with defects in
cell–cell adhesion compared to parental HCT116 (Figure 5A).
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Figure 1 Western blot of p300. Immunoblots showing p300 levels in
HCT116 WT, three independently targeted p300 clones (p300-1, p300-
2, p300-3) and two EF-wt rescue clones, where p300 was reintroduced,
with b-actin loading control. MT3 cells express the full-length p300
construct that was introduced in the EF-wt rescue clones, whereas
HCT116 express an truncated form. The experiment was repeated three
times and a representative blot is displayed.
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Figure 2 Immunofluorescent localisation of epithelial and mesenchymal
markers. Cells were stained for the epithelial markers E-cadherin, ZO-1, b-
catenin and the mesenchymal marker Vimentin (A). Experiments were
repeated three times; one representative field of view is represented for
each cell type. (B) Shows a magnified version of the nuclear staining of b-
catenin in the WT compared to the p300 cells.
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Figure 3 Western blots of (A) E-cadherin and (B) Vimentin. Total cell
lysates were analysed in duplicate from independent wells. Monoclonal
mouse primary antibodies and a sheep anti-mouse horseradish peroxidase-
conjugated secondary antibody were used for detection. (C) shows
staining a-tubulin on the same membrane as a loading control. The
experiments were repeated three times and a representative blot is
displayed.
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Reintroduction of p300 in ET-wt rescue clones could reverse this
phenotype. Expression of p300 in the rescue clones was confirmed
by Western blot (Figure 1). Quantification of this defect confirmed
that WT and ET-wt rescue clones indeed formed larger cell clusters
than p300 cells (Figure 5B). The difference between p300 clones
and WT or ET-wt rescue clones was significant for clusters up to
five cells (P-value o0.05) as well as for clusters above 10 cells
(P-value o0.005).
p300 cells have reduced levels of a2-integrin and reduced
adhesion to collagen-I and IV
To assess whether the absence of p300 results in abnormal
cellular expression of integrins, flow cytometry analyses of surface
integrins were performed. These experiments showed a decrease in
a2-integrin (Figure 6), with no significant change in a1-, a5-, aV-,
a6-, b1- and b3-integrin levels (data not shown). Major ligands of
a2b1-integrin are type-I and IV collagen. Therefore, we tested if
reduced integrin a2 levels affected cell –matrix adhesion in p300

cells. In vitro adhesion assays showed that p300 cells adhered less
to collagen I and matrigel, compared to HCT116 cells (P-value
o0.05). In contrast, no significant difference in adhesion could
be detected for fibronectin (P-value 40.05), which is not a ligand
of integrin a2 (Figure 7A). Inhibition of integrin a2-mediated
adhesion by addition of an integrin a2 blocking antibody reduced
adhesion of WT and p300 cells to collagen I and matrigel
significantly (for the highest antibody concentration Po0.05),
however, as expected not the adhesion to fibronectin (Figure 7B
and C).
These results show that HCT116 cells rely primarily on a2-
integrins for adhesion to collagen I and IV and suggest that the
decrease in cell surface integrin a2 levels seen in p300
 cells results
in reduced adhesion.
p300 cells show increased migration through collagen-I
and matrigel-coated membranes
Defects in adhesion are frequently associated with increased ECM
invasion and migration in cancer cells. To compare the motility of
HCT116 and p300 cells we used a transwell assay with type-I
collagen or matrigel-coated membranes. Migration through the
membrane was followed for 22 h in response to a chemotactic
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Figure 4 Western blots of (A) nuclear, (B) cytosolic extracts, (C)
statistical analysis of b-catenin and (D) Western blot of the membrane
fractionation for ZO-1. Nuclear and cytosolic extracts were prepared from
WT and p300 cells and analysed by Western blot. The b-catenin band at
92 kDa is indicated by an arrow. The band at 110 kDa is nonspecific and
serves well as internal standard. Experiments were repeated three times
and densitometry and statistical analysis of the three separate experiments
(in C) showed a significant increase of b-catenin in the p300 cells (P-value
o0.05). (D) Shows a blot of ZO-1 in membrane fractions of WT and
p300 cells. The band at 225 kDa indicated by an arrow corresponds to
ZO-1. The experiment was repeated three times and a representative blot
is shown.
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Figure 5 Adhesion defect on Matrigel growth after 18 h. (A) Matrigel
growth of WT, p300 and EF-wt rescue cell clusters. p300 clones (p300-
1, p300-2 and p300-3) cluster poorly into small clusters with ragged edges
compared to WT cells. This defect is reversed in EF-wt rescue clones.
Experiments were performed in triplicate, and the figure above shows a
representative example. (B) Graph of cluster size distribution in HCT116,
p300 and EF-wt rescue cells. The graph demonstrates the distribution of
cluster sizes in HCT116 vs the p300- and EF-wt rescue clones. Experiments
were performed in triplicate in all three p300- clones (p300-1. p300-2 and
p300-3) and two EF-wt rescue clones (EF-wt rescue 1 and EF-wt rescue 2).
Error bars indicate one standard deviation.
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gradient of FCS. In these assays, p300 cells demonstrated
markedly increased migration through both type-I collagen and
matrigel when compared to the WT HCT116 cells. Degradation of
ECM and cellular invasion is believed to be primarily dependent
on the proteolytic activity of metalloproteinase (MP) and serine
protease activity, either by direct degradation of the ECM or as
part of a protease activation cascade (DeClerck et al, 2004). We
showed that migration through type-I collagen was more
dependent on MP activity than serine protease activity: GM6001
or Galardin (a broad spectrum MP inhibitor) was more efficient
in inhibiting migration through type-1 collagen, compared to
aprotinin (a general serine proteinase inhibitor) (Figure 8A). The
inhibitor solvent DMSO alone did not affect invasion (data not
shown). In contrast, migration through matrigel was inhibited to a
similar extent by both aprotinin and Galardin (Figure 8B). In both
cases the combination of Galardin and aprotinin significantly
inhibited cell migration, but could not abrogate it completely. The
motility of the cells on plastic in a wounding assay was not affected
by the p300 disruption (data not shown).
Characterisation of MP and TIMP expression in HCT116
and p300 cells
Our results suggest that increased migration of p300 cells through
type-I collagen, could be MP dependent. We therefore proceeded
to quantify mRNA levels of known MMP, ADAM, their inhibitors,
the tissue inhibitor of metalloproteinase (TIMPs) and members
of the serine protease uPA cascade, to assess whether altered
expression of these proteins could account for the invasive
phenotype observed. Table 1 summarises the results of the real-
time RT–PCR analyses. The majority of MPs, TIMP-2 and -3, as
well as components of the uPA system were unchanged. However,
the mRNA levels of MMP-7, -15 and ADAM15 were significantly
decreased in p300 cells (Figure 9). MMP-7 and ADAM15 were
found to be below the limits of detection by Western blot (data not
shown).
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Figure 6 Comparison of integrin a2 cell surface levels in WT and p300

cells. The samples were measured in duplicate by flow cytometry. The
background fluorescence of the secondary antibody was subtracted from
the values. The experiment was repeated three times.
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Figure 7 Adhesion of WT and p300 cells. (A) Adhesion to different
ECM components. (B and C) show the inhibition of integrin a2-mediated
adhesion in the WT (B) and p300 cells (C). The concentrations in the
legend indicate the concentration of the adhesion blocking integrin a2
antibody present. Samples were measured in triplicate and experiments
repeated three times.
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Figure 8 Migration through matrigel (A) and collagen-I (B) coated
membranes in a chemotractive FCS gradient. Experiments were conducted
in triplicate and repeated three times. Where indicated metalloproteinase-
(Galardin at 25 mM) or the serine protease inhibitor (aprotinin at 100 mM)
were added to the medium in the well and the insert.
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DISCUSSION
p300 is considered to be a putative tumour-suppressor gene
because it is mutated, deleted or underexpressed in a number of
cancers. However, the mechanisms, through which p300 functions
to suppress tumorigenesis, remain controversial (Chan and La
Thangue, 2001; Iyer et al, 2004b). Using previously generated p300
deficient clones, derived from a colorectal carcinoma cell line, we
propose a novel pathway through which p300 may function as a
tumour suppressor.
Disrupting p300 in HCT116 cells induced changes characteristic
of EMT, a process thought to be important in carcinogenesis.
p300 cells had significant cell– cell adhesion defects, with
downregulation of E-cadherin, a major component of the epithelial
adherens junctions, and reduced aggregation in matrigel cultures.
Reintroduction of p300 could restore the aggregation phenotype.
In addition b-catenin was found to be increased in nuclear
fractions of p300 cells, which may contribute to intracellular
signalling inducing EMT. In colorectal tumours, tumour cells at
the invasion front display strong nuclear b-catenin, and the Tcf4-
b-catenin transcription factor complex is thought to be involved in
EMT (Brabletz et al, 2005). p300 cells also showed reduced
adhesion to the basement membrane components collagen I and
IV consequent to reduced cell surface levels of integrin a2. The
effect of integrin cell surface levels on the invasiveness of cancer
cells is debatable and probably depends on the system that is used
and relative surface levels and activation status of integrins. Sun
et al (1998) reported that reexpression of the a2b1-integrin in a
poorly differentiated breast carcinoma cell line, Mm5MT, resulted
in reversion of a malignant phenotype to a differentiated epithelial
phenotype. Reduction of integrin a6b4 via siRNA in MDA_MB_231
breast cancer cells resulted in decreased invasion on a laminin-
coated surface (Lipscomb et al, 2003).
Epithelial to mesenchyme transition is often characterised by an
increase in invasive potential in vitro, and this is believed to foster
the invasive and metastatic potential of tumour cells (Thiery,
2002). Comparing the migrative potential of parental HCT116 and
p300 cells in vitro, we found that p300 cells showed increased
migration through collagen I and matrigel-coated membranes.
It was not possible to assess migration through a thicker layer of
either gel (which would be more representative of cellular
invasion), since invasion rates were too low to obtain statistically
significant results. Nonetheless, we showed that migration through
matrigel was serine- and metalloproteinase dependent, whereas the
invasion through collagen I was metalloproteinase and only
marginally serine protease dependent.
Interestingly, increased migration was found to be independent
of expression levels of proteases involved in collagen or matrigel
degradation. Cell surface levels of MMP-14 (determined by flow
cytometry) and MMP-2 and MMP-9 activity (determined by
zymography) were not affected by the p300 disruption (data not
shown). Previous studies have shown that MMP-7 and MMP-14
can be upregulated as a consequence of the movement of b-catenin
to the nucleus and the increase in the Tcf4-b-catenin transcription
factor complex. Previous studies have shown that factors other
than b-catenin can also affect the MMP-7 and MMP-14 promoter
activity and the nature of such effectors in this system remain to be
elucidated (Crawford et al, 2001; Takahashi et al, 2002). Other
targets of this gene complex include CD44, which was also shown
to be downregulated in the microarray analysis of p300 cells. We
also noted that MMP-15 was significantly downregulated in p300
cells. Wound healing experiments did not show increased motility
of the p300 cells on a plastic culture dish (data not shown). These
data indicate that the migration in a chemotactic gradient is
supported by the degradation of the ECM coat. However, since
protease levels are largely unaffected by the p300 ablation, the
increased migration of the p300 cells is most likely due to
decreased cell– cell interactions and cell– matrix adhesion. The
disruption of cell– cell junctions may allow single p300 cells to
migrate more readily through the 8 mm pores of the membrane
compared to the clusters of the HCT116 WT cells, as many colon
cancer cell lines migrate as cohorts rather than single cells.
The data presented here proposes a novel mechanism through
which p300 could function as a tumour suppressor: p300
disruption promotes EMT and an aggressive cancer phenotype.
It has been suggested that histone deacetylase (HDAC) inhibitors,
which are currently being tested in clinical trials for cancer
therapy, function to selectively promote the expression of tumour-
suppressor genes. We propose an additional anticancer mechan-
ism, where HDAC inhibitors could promote p300 histone acetylase
Table 1 Summary of the effect of p300 ablation on MP, serine protease
and TIMP mRNA levels
MMP Effect of p300 ablation ADAM Effect of p300 ablation
1 Low expression 8 Low expression
2 Low expression 9 No change
3 No expression 10 No change
7 Downregulation** 12 No change
8 No expression 15 Downregulation**
9 No expression 17 No change
10 No change 19 No change
11 No change 28 No expression
12 No change 33 No expression
13 No change TIMP
14 No change 1 No expression
15 Downregulation** 2 No change
16 No expression 3 No change
17 No change 4 No expression
19 No change Plasmin system
23 No change uPAR No change
25 No change uPA No change
Plasminogen No expression
PAI-1 No change
PAI-2 No change
MP, serine protease and TIMP mRNA levels were determined in triplicate by pPCR
and repeated three times. Low expression signifies a cT-value o35, where
quantification becomes inaccurate. Downregulation **corresponds to a P-value
o0.001 when a mean of the three p300 clones is calculated vs the WT.
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Figure 9 The effect of p300 on the mRNA levels of MMP-7, -15 and
ADAM15. MP and TIMP mRNA levels were determined by qRCR in three
separate experiments that were conducted in triplicate. The relative
expression values were obtained by normalising the cT-values using the
cT-values of the 18S in the samples as reference, compensated for the
exponential fluorescence increase and set in relation to the WT values.
cT-values of MPs in WT: MMP-7: 30; MMP-15: 25; ADAM15: 24.
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activity, hence inhibiting EMT and increased invasiveness seen in
cancer cells.
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